OTL-200 in Patients With Late Juvenile Metachromatic Leukodystrophy (MLD)

Status Active, not recruiting

Clinical Trial Summary

OTL-200 is a cryopreserved dispersion for infusion containing autologous CD34+ cell enriched population that contains haematopoietic stem and progenitor cells (HSPC) transduced ex vivo using a lentiviral vector encoding the human arylsulfatase A (ARSA) gene. MLD is an autosomal recessive lysosomal storage disorder (LSD) characterized by severe and progressive demyelination affecting the central and peripheral nervous system. The aim of this clinical study is to assess the pharmacodynamic effect and long-term clinical efficacy and safety of OTL-200 in Late Juvenile MLD patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04283227
Study type	Interventional
Source	Orchard Therapeutics
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	January 17, 2022
Completion date	March 31, 2031

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00383448` - HSCT for High Risk Inherited Inborn Errors	Phase 2
Recruiting	`NCT05687474` - Baby Detect : Genomic Newborn Screening
Completed	`NCT01303146` - Efficacy METAZYM for the Treatment Metachromatic Leukodystrophy Treated With Hematopoietic Stem Cell Transplantation	Phase 2
Enrolling by invitation	`NCT03655223` - Early Check: Expanded Screening in Newborns
Active, not recruiting	`NCT04628364` - The Natural History of Metachromatic Leukodystrophy Study (HOME Study)
Enrolling by invitation	`NCT05368038` - ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
Active, not recruiting	`NCT01801709` - Intracerebral Gene Therapy for Children With Early Onset Forms of Metachromatic Leukodystrophy	Phase 1/Phase 2
Completed	`NCT00683189` - Effect of Warfarin in the Treatment of Metachromatic Leukodystrophy	N/A
Recruiting	`NCT02171104` - MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis	Phase 2
Active, not recruiting	`NCT02699190` - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Active, not recruiting	`NCT03392987` - A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD)	Phase 2
Recruiting	`NCT02559830` - Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy	Phase 1/Phase 2
Active, not recruiting	`NCT00639132` - The Natural History of Metachromatic Leukodystrophy
Completed	`NCT00004378` - Stem Cell Transplantation (SCT) for Genetic Diseases	N/A
Completed	`NCT00176904` - Stem Cell Transplant for Inborn Errors of Metabolism	Phase 2/Phase 3
Recruiting	`NCT03047369` - The Myelin Disorders Biorepository Project
Recruiting	`NCT04925349` - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Active, not recruiting	`NCT00005900` - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Active, not recruiting	`NCT01560182` - Gene Therapy for Metachromatic Leukodystrophy (MLD)	Phase 1/Phase 2
Completed	`NCT01586455` - Human Placental-Derived Stem Cell Transplantation	Phase 1